Report cover image

Palmoplantar Pustulosis (PPP)

Publisher Reach Market Research
Published Jan 01, 2022
Length 29 Pages
SKU # RMR19136507

Description

MarketVue®: Palmoplantar Pustulosis (PPP)

The MarketVue®: Palmoplantar Pustulosis market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.

Topics covered in this report:
• Disease overview: Review the disease pathophysiology and potential druggable targets
• Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
• Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
• Unmet needs: Identify opportunities to address treatment or disease management gaps
• Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
• Value and access: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing

Methodology:
Research for the MarketVue®: Palmoplantar Pustulosis report is supported by 6 qualitative interviews with key opinion leaders, a quantitative survey with 27 U.S. physicians and secondary research.

Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)

Key companies mentioned:
• AnaptysBio
• Boehringer Ingelheim
• Novartis
• Aristea Therapeutics
• Janssen
• Kyowa Kirin
• AbbVie
• Amgen
• CSL Behring
• Inmagene
• National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
• KHK
• Regeneron
• Eli Lilly
• Maruho

Key drugs mentioned:
• Acitretin
• Methotrexate
• Cyclosporine
• Etanercept (Enbrel)
• Adalimumab (Humira)
• Ixekizumab (Taltz)
• Brodalumab (Siliq, Kyntheum, Lumicef)
• Apremilast (Otezla)
• Ustekinumab (Stelara)
• Guselkumab (Tremfya)
• Risankizumab (Skyrizi)
• Imsidolimab
• Spesolimab (Spevigo)
• Secukinumab (Cosentyx)
• RIST4721
• CSL324
• Anumigilimab
• IMG-008
• REGN 6490
• Anakinra
• LY3041658
• Maxacalcitol

Please note: the online download version of this report is for a global site license.

Table of Contents

29 Pages
1. DISEASE OVERVIEW
A recurrent inflammatory disorder causing pustules on the hands and feet
Figure 1.1 – Conditions related to PPP
Disease pathogenesis
Figure 1.2. Autoimmune and autoinflammatory drivers of PPP disease pathogenesis
Figure 1.3 – Treatments effective in psoriasis are not effective in PPP
PPP is a distinguishable disease
Figure 1.4. Clinical and genetic differences between pustular psoriasis subtypes
2. EPIDEMIOLOGY & PATIENT POPULATIONS
Disease definition
Figure 2.1 – G6 prevalent cases of PPP by region
Table 2.1 – Prevalent and drug-treated populations of PPP in the U.S. and EU5
3. CURRENT TREATMENT
Overview
Figure 3.1 – Treatment goals for PPP
Standard of care
Figure 3.2 – Current treatment patient share
TNF inhibitors and IL-17 inhibitors are the most commonly used biologics in PPP
Figure 3.3 – Dermatologist-reported biologic use in PPP patients by drug class
Figure 3.4. Percentage of PPP patients who proceed from first-line to a second-line biologic
Figure 3.5 – Dermatologist preferred second-line biologic
Dermatologists choose biologics that are effective in psoriasis
Treatment decisions for PPP
Figure 3.6 – Treatment algorithm for PPP
Dermatologists tend to categorize PPP as a form of psoriasis
Figure 3.7 – Dermatologists’ opinion on the relationship between PPP and psoriasis
Figure 3.8. Evolution of PPP as a distinct indication
Current PPP treatment options are minimally effective
Table 3.1 – Upside and downsides of currently off-label PPP treatments
Current treatment options have their limitations
Key treatment dynamics that shape disease management and drug use
Table 3.2 – Must-know PPP treatment dynamics for now and the future
Figure 3.9 – Percentage of PPP patients who are not achieving satisfactory outcomes with current treatments
PPP has a severe psychosocial and quality of life impact on patients
Figure 3.10 – Dermatologists’ rating of the impact of PPP on patients
First approved therapies for PPP likely to be label expansions
Figure 3.11 – Important dynamics of PPP market evolution
4. UNMET NEED
Overview
Top unmet needs in PPP
Figure 4.1 – Dermatologist-reported unmet needs in PPP
Physician perspectives on unmet needs in PPP
Figure 4.2 – U.S. dermatologists ranking of the need for new treatments in dermatology
5. PIPELINE ANALYSIS
Drug development for PPP
Figure 5.1 – Number of clinical stage therapies addressing unmet needs in PPP
Figure 5.2 – Percent of U.S. dermatologists rating PPP emerging therapy target as “promising”
Opinions are mixed on which MOA is the most promising
Summary of clinical-stage emerging PPP therapies
Table 5.1 – Emerging PPP therapies, Phase 1 to Phase 3
Competitor pipeline overview
Figure 5.3. – Current pipeline shows several therapies in varying stages of development
6. VALUE & ACCESS
Overview
Table 6.1 – Current therapy pricing, US 2021
Biologics require prior authorization on commercial insurance plans
Figure 6.1 – Reimbursement and Access considerations for emerging therapies in PPP
Medicare reimbursement stands to be a high barrier for patient access to novel PPP therapies
Regulatory considerations in PPP
Figure 6.2. – Key regulatory factors in PPP
7. METHODOLOGY
Primary market research approach
Epidemiology methodology
Disease overview

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us